( May 18, 2026, 4:08 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court will let stand a final judgment of $193 million for a qui tam relator who sued Eli Lilly & Co. for reporting falsely deflated drug prices to the government in order to profit off of drug rebate programs, denying on May 18 a petition for a writ of certiorari from a drug manufacturer that argued that qui tam claims under the False Claims Act (FCA) are unconstitutional....